Serum prostate specific antigen (PSA) has been widely used as the optimal conventional serum marker for prostate cancer in the clinical setting, especially as a marker for initial diagnosis, as it can predict cancer risk and treatment outcome [6]. This evidence concerns the gene KLK3 and cancer.